TrovaGene Inc (NASDAQ:TROV) has been assigned a $4.00 price target by research analysts at Maxim Group in a report released on Thursday. The firm currently has a “buy” rating on the medical research company’s stock. Maxim Group’s target price would indicate a potential upside of 412.10% from the stock’s current price.

Other equities analysts have also recently issued reports about the stock. S&P Equity Research upped their price target on shares of TrovaGene from $1.55 to $1.80 in a research note on Friday, March 10th. Cantor Fitzgerald set a $8.00 price target on shares of TrovaGene and gave the stock a “buy” rating in a research note on Saturday, March 18th. Zacks Investment Research cut shares of TrovaGene from a “buy” rating to a “hold” rating in a research note on Wednesday, March 15th. Finally, Piper Jaffray Companies cut shares of TrovaGene from a “neutral” rating to an “underweight” rating in a research note on Thursday, March 16th.

TrovaGene (NASDAQ:TROV) traded up 2.7493% during mid-day trading on Thursday, reaching $0.7811. 186,637 shares of the company traded hands. TrovaGene has a 52 week low of $0.65 and a 52 week high of $5.98. The stock’s 50 day moving average price is $0.93 and its 200 day moving average price is $2.04. The firm’s market capitalization is $24.19 million.

TRADEMARK VIOLATION NOTICE: This news story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/05/13/trovagene-inc-trov-pt-set-at-4-00-by-maxim-group.html.

Large investors have recently modified their holdings of the stock. KCG Holdings Inc. boosted its stake in shares of TrovaGene by 560.1% in the first quarter. KCG Holdings Inc. now owns 210,301 shares of the medical research company’s stock worth $242,000 after buying an additional 178,440 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of TrovaGene by 5.3% in the first quarter. Geode Capital Management LLC now owns 197,459 shares of the medical research company’s stock worth $227,000 after buying an additional 9,881 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of TrovaGene by 0.3% in the first quarter. Vanguard Group Inc. now owns 772,916 shares of the medical research company’s stock worth $889,000 after buying an additional 2,070 shares during the last quarter. Teachers Advisors LLC boosted its stake in shares of TrovaGene by 28.5% in the fourth quarter. Teachers Advisors LLC now owns 61,834 shares of the medical research company’s stock worth $130,000 after buying an additional 13,714 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of TrovaGene by 9.6% in the fourth quarter. State Street Corp now owns 432,910 shares of the medical research company’s stock worth $910,000 after buying an additional 38,095 shares during the last quarter. 27.88% of the stock is currently owned by hedge funds and other institutional investors.

TrovaGene Company Profile

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

5 Day Chart for NASDAQ:TROV

Receive News & Ratings for TrovaGene Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc and related companies with MarketBeat.com's FREE daily email newsletter.